

China

Western Pacific Region



I. Epidemiological profile

Population (UN)	2016	%
Number of active foci	3	
Number of people living within active foci	2,570	0
Malaria-free (0 cases)	1,410,000,000	100
Total	1,411,400,000	

Parasites and vectors	
Plasmodium species:	<i>P. falciparum</i> (0%), <i>P. vivax</i> (100%)
Major anopheles species:	<i>An. sinensis</i> , <i>An. anthropophagus</i> , <i>An. dirus</i> , <i>An. minimus</i>
Reported confirmed cases (health facility):	3
Confirmed cases at community level:	-
Reported deaths:	0

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/ LLINs distributed free of charge	Yes	2003
	ITNs/ LLINs distributed to all age groups	Yes	2000
IRS	IRS is recommended	Yes	2000
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	No	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2000
	Malaria diagnosis is free of charge in the public sector	No	-
Treatment	ACT is free of charge for all ages in public sector	Yes	2006
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	1970
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	1970
	System for monitoring adverse reactions to antimalarials exists	Yes	1970
Surveillance	ACD for case investigation (reactive)	Yes	2010
	ACD of febrile cases at community level (pro-active)	Yes	2010
	Mass screening is undertaken	Yes	2010
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-
	Foci and case investigation undertaken	Yes	2010
	Case reporting from private sector is mandatory	Yes	1956

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of <i>P. falciparum</i>	ART+NQ; ART-PPQ; AS+AQ; DHA-PPQ	2009
Treatment failure of <i>P. falciparum</i>	-	-
Treatment of severe malaria	AM; AS; PYR	2009
Treatment of <i>P. vivax</i>	CQ+PQ(8d)	2006
Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.75 mg/kg(8 days)
Type of RDT used		-

Therapeutic efficacy tests (clinical and parasitological failure, %)


Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
DHA-PPQ	2012-2015	0	0	6	42 days	6	<i>P. falciparum</i>
DHA-PPQ	2010-2011	0	0	0	28 days	3	<i>P. falciparum</i>
CQ	2010-2015	0	0	2.4	28 days	9	<i>P. vivax</i>

Insecticide resistance tests (mosquito mortality, %)

Insecticide class	Years	Min	Mean	Max	No. of sites	Species
Carbamates	2011-2013	0.1	0.8	1	13	<i>An. sinensis s.l.</i> , <i>Anopheles spp.</i>
Organophosphates	2010-2014	0.1	0.7	1	42	<i>An. minimus s.l.</i> , <i>An. sinensis s.l.</i> , <i>An. vagus</i>
Organochlorines	2010-2014	0	0.5	1	51	<i>An. minimus s.l.</i> , <i>An. sinensis s.l.</i> , + other
Pyrethroids	2010-2016	0	0.4	1	95	<i>An. minimus s.l.</i> , <i>An. sinensis s.l.</i> , + other

III. Financing


Sources of financing




Government expenditure by intervention in 2016

IV. Coverage


Coverage of ITN and IRS




Cases tested



Cases treated




Cases tracked




V. Impact

Confirmed malaria cases per 1000 and ABER



Number of malaria cases



Notes:

Reported confirmed cases and reported deaths are indigenous only